Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ENLV
STRONG SELLREMOVEEnlivex Ltd. · Healthcare · Israel · $146M · Avg Vol: $240K/d
Enlivex is a micro-cap biotech company with high binary clinical trial risks. This violates the Warren Buffett margin of safety and Terry Smith quality lenses, which demand predictable, high-ROIC businesses.
COMPANY DESCRIPTION
Enlivex Ltd. is a clinical-stage biotechnology company focused on developing Allocetra™, a novel cell-based immunotherapy designed to rebalance the immune system in patients suffering from life-threatening inflammatory and autoimmune conditions. The company's competitive edge lies in its unique approach to modulating the immune system, aiming to prevent and reverse cytokine storms and organ dysfunction. It operates as a specialized biotech firm, with its lead candidate showing promise in severe indications such as sepsis and COVID-19.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — |
| EPS | -0.81 | -0.13 | -0.12 | -0.07 | — | — |
| Shares | — | 241.0M | 241.0M | 241.0M | 237.4M | -1.5% |
| Debt | — | 4.8M | 1.0M | 0.5M | 0.6M | -49.1% |
| Equity | — | 56.8M | 30.1M | 23.6M | 1.9B | 224.1% |
| Op CF | — | -24.0M | -23.5M | -13.0M | -10.4M | — |
| Inv CF | — | 62.5M | -26.0M | 9.1M | -1.3M | — |
| Fin CF | — | 0.1M | 0.4M | 6.5M | 10.4M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ENLV are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ENLV | Enlivex Ltd.(you) | $146M | 18 | STRONG SELL |
| PYPD | PolyPid Ltd. | $92M | 24 | SELL |
| ENTX | Entera Bio Ltd. | $70M | 4 | STRONG SELL |
| SLGL | Sol-Gel Technologies Ltd. | $246M | 39 | HOLD |
| DRTS | Alpha Tau Medical Ltd. | $890M | 36 | HOLD |
| CGEN | Compugen Ltd. | $196M | 93 | STRONG BUY |
| NNOX | Nano-X Imaging Ltd. | $112M | 8 | STRONG SELL |
| 1696.HK | Sisram Medical Ltd | $134M | 64 | HOLD |
| BVC.L | BATM Advanced Communications Ltd. | $69M | 56 | HOLD |
| BWAY | BrainsWay Ltd. | $585M | 83 | STRONG BUY |
Peer medians: ROE 1.1% · P/E 15.2x · Gross margin 36.8%